New ELUCIGENE CF 29 ASR from Orchid Diagnostics

Orchid Diagnostics is pleased to announce the availability of ELUCIGENE CF 29 ASR reagents for the detection of 29 cystic fibrosis mutations using ARMS™ technology. The ELUCIGENE reagents have been developed specifically to meet the requirements of the Laboratory Standards and Guidelines for Population-Based Cystic Fibrosis Carrier Screening published by the American College of Medical Genetics. CF 29 consists of four primer mixes, dilution buffer and a gel loading dye. It is capable of detecting the core panel of 25 mutations selected by the ACMG in addition to four others. ELUCIGENE's use of ARMS allele specific amplification is able to discriminate between the benign 506, 507 and 508 polymorphisms directly, eliminating the need for reflex testing. ARMS is a simple yet accurate technique that only requires a thermal cycler and gel electrophoresis equipment. Poly-T ASR reagents are available separately for determination of intron 8 Poly-T status when appropriate (i.e. R117H carriers).

The “New Products” page is designed to offer you news and information from businesses serving the genetics community. We welcome your submissions. All submissions are subject to review by the Editor. For more information, contact Al Lucchesi, National Accounts Manager, Lippincott Williams & Wilkins, 530 Walnut Street, Philadelphia, PA 19106; phone 215-521-8409; fax 215-521-8411; email alucches@lww.com.